Search Results - "Seay, TE"

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31 by TAN-CHIU, Elizabeth, YOTHERS, Greg, VOGEL, Victor G, SEAY, Thomas E, RASTOGI, Pnya, MAMOUNAS, Eleftherios P, WOLMARK, Norman, BRYANT, John, ROMOND, Edward, GEYER, Charles E, EWER, Michael, KEEFE, Deborah, SHANNON, Richard P, SWAIN, Sandra M, BROWN, Ann, FEHRENBACHER, Louis

“…Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction…”
Get full text

Oral Uracil and Tegafur Plus Leucovorin Compared With Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project Protocol C-06 by LEMBERSKY, Barry C, WIEAND, H. Samuel, COLMAN, Lauren K, SORAN, Atilla, YOTHERS, Greg, WOLMARK, Norman, PETRELLI, Nicholas J, O'CONNELL, Michael J, COLANGELO, Linda H, SMITH, Roy E, SEAY, Thomas E, GIGUERE, Jeffrey K, MARSHALL, M. Ernest, JACOBS, Andrew D

“…The primary aim of this study was to compare the relative efficacy of oral uracil and tegafur (UFT) plus leucovorin (LV) with the efficacy of weekly…”
Get full text

Abstract S1-05: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42 by Mamounas, EP, Bandos, H, Lembersky, BC, Geyer, CE, Fehrenbacher, L, Graham, ML, Chia, SL, Brufsky, AM, Hennessy, BT, Soori, GS, Dakil, SR, Seay, TE, Wade, JL, McCarron, EC, Paik, S, Swain, SM, Wickerham, DL, Wolmark, N

“…Background: Extending adjuvant endocrine therapy (tx) after 5 yrs of tamoxifen (Tam) with either Tam or an AI improves disease-free survival (DFS) in…”
Get full text

Abstract S6-04: Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy by Ganz, PA, Cecchini, RS, Julian, TB, Margolese, RG, Costantino, JP, Vallow, LA, Albain, KS, Whitworth, PW, Cianfrocca, ME, Brufsky, A, Gross, HM, Soori, GS, Hopkins, JO, Fehrenbacher, L, Sturtz, K, Wozniak, TF, Seay, TE, Mamounas, EP, Wolmark, N

“…Background The clinical results of NSABP B-35, phase III trial comparing 1 mg/day A to 20 mg/day tam, each given for 5 years, were reported at ASCO 2015. B-35…”
Get full text

OT1-02-05: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy to Radiation Therapy (RT) Alone for Women with HER2−Positive DCIS Resected by Lumpectomy: NSABP B-43 by Julian, TB, Anderson, SJ, Cobleigh, MA, Siziopikou, KP, Arthur, DW, Zheng, P, Mamounas, EP, Pajon, ER, Behrens, RJ, Chu, L, Leasure, NC, Atkins, JN, Polikoff, J, Seay, TE, McCaskill-Stevens, W, Rabinovitch, R, Wolmark, N

“…Background Because a substantial portion of DCIS is ER negative and overexpresses HER2, therapy targeting this protein is a promising strategy for…”
Get full text

Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study by Rothenberg, M. L., Benedetti, J. K., Macdonald, J. S., Seay, T. E., Neubauer, M. A., George, C. S., Tanaka, M. S., Giguere, J. K., Pruitt, B. T., Abbruzzese, J. L.

“…Background: Eniluracil is a potent, irreversible inactivator of dihydropyrimidine dehydrogenase, the major catabolic enzyme for 5-fluorouracil (5-FU)…”
Get full text

Phase II evaluation of suramin in advanced renal cell carcinoma: A Southwest Oncology Group study by Schroder, Louis E, Lew, Danika, Flanigan, Robert C, Eisenberger, Mario A, Seay, Thomas E, Hammond, Neel, Needles, Burton M, Crawford, E.David

“…Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with…”
Get full text

Amphotericin B modifications of peripheral blood lymphocyte and tonsil lymphocyte responses to concanavalin A by Seay, T E, Inman, F P

“…Peripheral blood lymphocytes (PBL) were shown previously to be activated to incorporate 3H-thymidine by concanavalin A (con A). Amphotericin B (Am B) was…”
Get more information